Ifinatamab Deruxtecan May Benefit Patients with Recurrent or Progressive ES-SCLC

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Sep 7, 2025-

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

Ifinatamab Deruxtecan Shows Activity in Previously Treated ES-SCLC

Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.

Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High

In a groundbreaking advancement for small cell lung cancer (SCLC) therapy, recent data unveiled at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) offers new hope to patients grappling with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC). Researchers presented compelling evidence supporting the efficacy of ifinatamab deruxtecan (I-DXd), a novel B7-H3–targete…

48% Response Rate: Breakthrough Cancer Drug Shows Promise in Advanced Lung Cancer Patients Trial

Phase 2 trial of ifinatamab deruxtecan achieved 48.2% response rate in extensive-stage small cell lung cancer patients, with 5.3-month duration of response and 10.3-month survival rate.